Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI) both struggled to generate meaningful Day-One momentum Friday, with neither deal producing a Bull signal despite very different opening setups. Odyssey opened at a premium to its $18 IPO price, trading as high as $20.30 shortly after the open, but the move lacked the type of sustained institutional follow through typically associated with stronger IPO debuts. IPO Prophet’s posture on ODTX was initially neutral during the opening trade before sentiment shifted bearish early in the session as momentum deteriorated and shares steadily faded throughout the afternoon, ultimately closing at $16.42.
Mobia Medical faced a more difficult setup from the start. The company priced at $15 but opened below issue price at $14 and failed to establish any meaningful upside traction during most of the session. IPO Prophet maintained a bearish posture from the open as shares trended lower throughout the day before a late-session bounce helped trim losses into the close. MOBI finished the session at $11.77 after trading as low as $10.19 intraday.
The broader takeaway from Friday’s action was the lack of sustained appetite for lower-conviction IPOs despite a calendar that continues to build. While Odyssey initially attracted enough interest to open above issue price, neither transaction generated the type of demand profile needed to trigger a Bull signal or sustain upside momentum through the close.
Attention now shifts to what is shaping up to be one of the busiest IPO stretches of the year. Expected deals next week include Fervo Energy (FRVO), Cerebras Systems (CBRS), GMR Solutions (GMRS), Blackstone Digital Infrastructure Trust (BXDC), and EagleRock Land (EROK), while Friday also brought several notable new filing announcements expected to reach the market in the coming weeks. Quantinuum (QNT), the quantum computing company backed by Honeywell, filed publicly alongside Applied Aerospace and Defense (AADX), while Neutron Holdings, the parent company of Lime (LIME), also officially entered the IPO pipeline.
With both the size and number of offerings increasing rapidly, the next several weeks could provide a much clearer read on whether institutional demand is expanding across the broader IPO market or remaining concentrated in select higher-quality names.